105,99 €
Mehr erfahren.
- Herausgeber: John Wiley & Sons
- Kategorie: Fachliteratur
- Sprache: Englisch
Inflammatory Bowel Diseases: A Clinician’s Guide provides practical guidance for the diagnosis and management of those suspected or known to have one of the forms of these complex diseases. It is perfect both for gastroenterology trainees learning to care for these patients and the experienced physician as a concise and practical resource for day to day use.
Written by the experts, Inflammatory Bowel Diseases: A Clinician’s Guide is an essential tool for all gastroenterologists managing patients with inflammatory bowel disease.Sie lesen das E-Book in den Legimi-Apps auf:
Seitenzahl: 392
Veröffentlichungsjahr: 2017
Ähnliche
Table of Contents
Cover
Title Page
Preface
Section I: Pathogenesis and Clinical Features
1 Epidemiology and Pathogenesis
Epidemiology
Pathogenesis
Case Studies and Multiple Choice Questions
References
Answers to Questions
2 Clinical Features and Diagnosis of Crohn’s Disease
Clinical Features
Disease Course and Natural History
Diagnosis
Case Studies and Multiple Choice Questions
References
Answers to Questions
3 Clinical Features and Diagnosis of Ulcerative Colitis
Clinical Features
Disease Course and Natural History
Diagnosis
Differential Diagnosis (UC and CD)
Case Studies and Multiple Choice Questions
References
Answers to Questions
4 Extraintestinal Manifestations of Inflammatory Bowel Diseases
Arthritis and Arthropathy
Metabolic Bone Disease
Cutaneous Manifestations
Hepatobiliary Manifestations
Ophthalmologic Manifestations
Renal Complications
Thromboembolic and Cardiovascular Complications
Case Studies and Multiple Choice Questions
References
Answers to Questions
Section II: Therapeutic Agents
5 Aminosalicylates
Efficacy in Ulcerative Colitis
Efficacy in Crohn’s Disease
Safety
Multiple Choice Questions
References
Answers to Questions
6 Corticosteroids
Efficacy in Ulcerative Colitis
Efficacy in Crohn’s Disease
Safety
Case Studies and Multiple Choice Questions
References
Answers to Questions
7 Immunomodulators
Thiopurines
Methotrexate
Calcineurin Inhibitors
Case Studies and Multiple Choice Questions
References
Answers to Questions
8 Biologic Therapies
Infliximab
Adalimumab
Certolizumab Pegol
Golimumab
Natalizumab
Vedolizumab
Newer Therapies
Case Studies and Multiple Choice Questions
References
Answers to Questions
9 Antibiotics
Efficacy in Ulcerative Colitis
Efficacy in Crohn’s Disease
Other Microbial Modification Methods – Probiotics and Fecal Microbiota Transplantation
Multiple Choice Questions
References
Answers to Questions
Section III: Management
10 Medical Management of Ulcerative Colitis
Assessment of Extent, Activity, and Severity
Limited Colitis – Proctitis, Proctosigmoiditis, and Left‐sided Colitis
Pancolitis
Case Studies and Multiple Choice Questions
References
Answers to Questions
11 Medical Management of Crohn’s Disease
Mild to Moderate Disease
Moderate to Severe Disease
Case Studies and Multiple Choice Questions
References
Answers to Questions
12 Surgical Management of Inflammatory Bowel Diseases
Surgery for Ulcerative Colitis
Surgery for Crohn’s Disease
Case Studies and Multiple Choice Questions
References
Recommended Reading
Answers to Questions
13 Complications of Inflammatory Bowel Diseases
Complications of Ulcerative Colitis
Complications of Crohn’s Disease
Case Studies and Multiple Choice Questions
References
Answers to Questions
Section IV: Special Considerations
14 Nutrition in Inflammatory Bowel Diseases
Malnutrition and Micronutrient Deficiencies
Dietary Therapies for Inflammatory Bowel Diseases
Case Studies and Multiple Choice Questions
References
Answers to Questions
15 Pregnancy, Conception, and Childbirth
Fertility
Effect of Pregnancy on Disease
Effect of Disease on Pregnancy
Maternal Medication Use During Pregnancy
Paternal Medication Use
Inheritance
Case Studies and Multiple Choice Questions
References
Answers to Questions
16 Inflammatory Bowel Disease During Childhood and Adolescence
Epidemiology and Clinical Features
Treatment of Pediatric Inflammatory Bowel Disease
Very Early‐onset Inflammatory Bowel Disease
Transition of Care in Pediatric Crohn’s Disease
Case Studies and Multiple Choice Questions
References
Answers to Questions
Index
End User License Agreement
List of Tables
Chapter 01
Table 1.1 Effect of environmental risk factors on risk of development of Crohn’s disease or ulcerative colitis.
Chapter 02
Table 2.1 Clinical, endoscopic, and histologic findings differentiating Crohn’s disease from ulcerative colitis.
Table 2.2 The Montreal classification of disease location and behavior in Crohn’s disease.
Table 2.3 The Crohn’s disease activity index (CDAI): a CDAI <150 indicates remission, 150–220 indicates mild disease, 220–450 indicates moderate disease, and >450 indicates severe disease.
Table 2.4 Table for calculation of Crohn’s disease endoscopic index of severity (CDEIS).
Table 2.5 Rutgeerts classification of post‐operative recurrence in Crohn’s disease.
Chapter 03
Table 3.1 Montreal classification of extent and severity of ulcerative colitis.
Table 3.2 Truelove–Witts classification of severity of ulcerative colitis.
Table 3.3 Ulcerative colitis endoscopic index of severity.
Table 3.4 Histologic findings in ulcerative colitis and acute self‐limited colitides.
Chapter 04
Table 4.1 Major extraintestinal manifestations of inflammatory bowel diseases.
Table 4.2 Recommendations for screening and treatment of osteoporosis in patients with inflammatory bowel diseases.
Chapter 05
Table 5.1 Preparations of 5‐aminosalicylic acid derivatives in the United States.
Chapter 06
Table 6.1 Side effects of systemic corticosteroids.
Chapter 08
Table 8.1 Dose and route of administration of biologic agents in Crohn’s disease and ulcerative colitis.
Chapter 10
Table 10.1 Components of the Mayo clinical and endoscopic scoring system in ulcerative colitis.
Table 10.2 Stepwise management of acute severe colitis.
Chapter 12
Table 12.1 Classification of ileal pouch disorders and associated complications.
Chapter 13
Table 13.1 Risk factors for colorectal neoplasia in patients with inflammatory bowel disease.
Chapter 14
Table 14.1 Common micronutrient deficiency in inflammatory bowel diseases: causes and treatment.
Chapter 15
Table 15.1 Medication categories and safety during pregnancy and breastfeeding.
Chapter 16
Table 16.1 Barriers to successful transition of care of adolescents with inflammatory bowel disease.
List of Illustrations
Chapter 01
Figure 1.1 Geographic variation in incidence of Crohn’s disease and ulcerative colitis.
Figure 1.2 Inflammatory bowel disease develops as a result of a complex interplay between genetics, the microbiome, immunologic dysregulation, and the external environment.
Chapter 02
Figure 2.1 Clinical image of perianal Crohn’s disease demonstrating multiple perineal fistulae.
Figure 2.2 Natural history of Crohn’s disease is characterized by progression with an increasing proportion of penetrating and stricturing complications.
Figure 2.3 Endoscopic appearance of colonic Crohn’s disease with wide ulcerations, edema, and intervening areas of normal mucosa.
Figure 2.4 Histologic appearance of the small bowel in Crohn’s disease demonstrating a single discrete non‐necrotizing granuloma.
Figure 2.5 Active terminal ileal Crohn’s disease on CTE demonstrating wall thickening, mucosal hyperenhancement, and mesenteric inflammation.
Chapter 03
Figure 3.1 Mayo endoscopic score for assessment of disease activity in ulcerative colitis.
Figure 3.2 Biopsy from an individual with ulcerative colitis. Colonic mucosa with histologic evidence of chronic colitis. Note the marked crypt architectural distortion including crypt branching. An increased number of lymphocytes and plasma cells are present throughout the lamina propria.
Figure 3.3 Approach to new diagnosis of ulcerative colitis.
Chapter 04
Figure 4.1 Plain radiograph of right sacroiliac joint in a patient with ulcerative colitis and sacroileitis.
Figure 4.2 Image of a patient with erythema nodosum.
Figure 4.3 Pyoderma gangrenosum in a patient with inflammatory bowel disease.
Figure 4.4 Endoscopic retrograde cholangiographic image of a patient with PSC demonstrating beading and dilation of the intrahepatic ducts.
Figure 4.5 Uveitis in a patient with inflammatory bowel disease.
Chapter 05
Figure 5.1 Dose response to delayed release oral mesalamine (4.8 g per day compared with 2.4 g per day) in mild to ‐moderate ulcerative colitis.
Chapter 06
Figure 6.1 One‐year outcomes after initiation of systemic corticosteroid therapy in Crohn’s disease and ulcerative colitis. CS, corticosteroid.
Chapter 07
Figure 7.1 Metabolism of thiopurines.
Figure 7.2 Algorithm for management of loss of response to thiopurines.
Chapter 08
Figure 8.1 Efficacy of infliximab maintenance in ulcerative colitis: proportion of patients with a sustained clinical response (a) and in sustained clinical remission (b) in ACT 1 and ACT 2.
Figure 8.2 Efficacy of infliximab in Crohn’s disease: clinical response and clinical remission for week‐2 responders in the ACCENT I randomized trial. Groups I, II, and III indicate patients randomized to placebo, 5 mg kg
–1
, and 10 mg kg
–1
maintenance regimens, respectively.
Figure 8.3 Algorithm for management of loss of response to infliximab. CRP, C‐reactive protein; NSAIDs, non‐steroidal anti‐inflammatory drugs; IFX, infliximab; ATI, antibodies to inlfiximab; anti‐TNF, monoclonal antibodies to TNF‐α; IMM, immunomodulator.
Figure 8.4 Comparative effectiveness of infliximab, azathioprine, and combination therapy: corticosteroid‐free clinical remission (a) and mucosal healing (b) at week 26 in the SONIC trial.
Figure 8.5 Efficacy of adalimumab maintenance therapy in Crohn’s disease. Clinical remission at weeks 26 and 56 (a) and clinical remission over time (b) in randomized responder population (week 4 responders) in the CHARM trial.
Figure 8.6 Efficacy of vedolizumab in ulcerative colitis: the GEMINI trial demonstrating improvement in partial Mayo score with placebo and vedolizumab every 4 weeks and every 8 weeks in patients with ulcerative colitis.
Chapter 10
Figure 10.1 Algorithm for management of limited distal ulcerative colitis. 5‐ASA, 5‐aminosalicylates.
Figure 10.2 Algorithm for management of mild‐to‐moderate pancolitis. 5‐ASA, 5‐aminosalicylates; anti‐TNF, monoclonal antibodies to tumor necrosis factor alpha; VDZ, vedolizumab.
Figure 10.3 Algorithm for management of moderate to severe UC. Anti‐TNF, monoclonal antibodies to tumor necrosis factor alpha; VDZ, vedolizumab; IMM, immunomodulators.
Chapter 11
Figure 11.1 Algorithm for management of mild‐to‐moderate CD. Anti‐TNF, monoclonal antibodies to tumor necrosis factor alpha; VDZ, vedolizumab; NAT, natalizumab; IMM, immunomodulator.
Figure 11.2 Algorithm for management of moderate‐to severe CD. Anti‐TNF, monoclonal antibodies to tumor necrosis factor alpha; IMM, immunomodulator.
Chapter 12
Figure 12.1 Three‐stage surgery for surgery for ulcerative colitis – total proctocolectomy with an ileal pouch–anal anastomosis (IPAA).
Figure 12.2 Algorithm for management of pouchitis. Anti‐TNF, monoclonal antibodies to tumor necrosis factor alpha; 5‐ASA, 5‐aminosalicylates.
Figure 12.3 Algorithm for postoperative prophylaxis to prevent recurrence in Crohn’s disease. Anti‐TNF, monoclonal antibodies to tumor necrosis factor alpha; 5‐ASA, 5‐aminosalicylates; i0–i4, Rutgeerts postoperative classification.
Chapter 13
Figure 13.1 Computed tomography images of toxic megacolon in a patient with severe ulcerative colitis.
Figure 13.2 Magnetic resonance enterography image of terminal ileal stricture and high‐grade small‐bowel obstruction in a patient with Crohn’s disease.
Figure 13.3 Algorithm for management of intra‐abdominal abscess. Anti‐TNF, monoclonal antibodies to tumor necrosis factor alpha; IMM, immunomodulator.
Figure 13.4 Types of perianal fistulae in Crohn’s disease.
Figure 13.5 An axial T2 fat‐suppressed image showing a trans‐sphincteric fistula with a horseshoe abscess and also an additional abscess extending posteriorly into the left ischioanal fossa.
Guide
Cover
Table of Contents
Begin Reading
Pages
i
ii
ix
x
1
3
4
5
6
7
8
9
10
13
14
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
33
34
35
36
37
38
39
40
41
42
43
44
45
46
49
50
51
52
53
54
55
56
57
58
59
60
61
63
65
66
67
68
69
70
71
72
73
75
76
77
78
79
80
81
82
83
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
123
124
125
126
127
128
129
131
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
149
150
151
152
153
154
155
156
157
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
189
191
192
193
194
195
196
197
199
200
201
202
203
204
205
206
209
210
211
212
213
214
217
218
219
220
221
222
Inflammatory Bowel Diseases
A Clinician’s Guide
Ashwin N. Ananthakrishnan MD MPH
Assistant Professor of MedicineHarvard Medical SchoolDirectorCrohn’s and Colitis CenterMassachusetts General HospitalBoston, MA, USA
Ramnik J. Xavier MD
Kurt Isselbacher Professor of MedicineHarvard Medical School;Chief of GastroenterologyMassachusetts General Hospital;Institute MemberBroad Institute of MIT and HarvardBoston, MA, USA
Daniel K. Podolsky MD
PresidentUniversity of Texas Southwestern Medical CenterProfessor of Internal MedicineUniversity of Texas Southwestern Medical SchoolDallas, TX, USA
This edition first published 2017 © 2017 by John Wiley & Sons Ltd
Registered OfficeJohn Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK
Editorial Offices9600 Garsington Road, Oxford, OX4 2DQ, UKThe Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK.111 River Street, Hoboken, NJ 07030‐5774, USA
For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley‐blackwell
The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.
Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.
The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by health science practitioners for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.
Library of Congress Cataloging‐in‐Publication Data
Names: Ananthakrishnan, Ashwin N., author. | Xavier, Ramnik J., author. | Podolsky, Daniel Kalman, author.Title: Inflammatory bowel diseases : a clinician’s guide / Ashwin N. Ananthakrishnan, Ramnik J. Xavier, Daniel K. Podolsky.Description: Chichester, West Sussex, UK ; Hoboken, NJ : John Wiley & Sons, Inc., 2017. | Includes bibliographical references and index.Identifiers: LCCN 2017001705 (print) | LCCN 2017002995 (ebook) | ISBN 9781119077602 (cloth) | ISBN 9781119077619 (pdf) | ISBN 9781119077626 (epub)Subjects: | MESH: Inflammatory Bowel DiseasesClassification: LCC RC862.I53 (print) | LCC RC862.I53 (ebook) | NLM WI 420 | DDC 616.3/44–dc23LC record available at https://lccn.loc.gov/2017001705
A catalogue record for this book is available from the British Library.
Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.
Cover images: The image fifth from the left (inset) is reproduced with permission of Vikram Deshpande MD. (See the caption for figure 2.4 for more details.) All other images are courtesy of the authors.
Preface
Inflammatory bowel diseases (IBDs), comprising Crohn’s disease (CD) and ulcerative colitis (UC), are complex diseases that often have their onset during young adulthood. They have a protracted course characterized by periods of remission and relapse, and frequently result in hospitalization, surgery, and continued morbidity. Importantly, they also exert a significant impact on the individuals’ health‐related quality of life and work productivity. Physicians caring for patients with IBD encounter varied and often complex challenges. The importance of optimal decision‐making for the welfare of the patient cannot be overstated.
This book was developed to serve as a resource for practicing physicians, allied healthcare providers, and trainees who care for patients with Crohn’s disease and ulcerative colitis. Although exhaustive textbooks are available, this new handbook aims to provide a concise understanding of these disorders and practical guidance on approaches to diagnosis and treatment. Care of patients with IBD is integral to the practice of gastroenterology and frequently also encountered by internists, surgeons, pediatricians, and other physicians, in addition to nurses and other caregivers.
The past two decades have witnessed a significant revolution both in our understanding of the pathogenesis behind these complex diseases and in the availability of therapeutic options that have enhanced the ability to achieve clinical and endoscopic remission. Facilitated by advances in sequencing tools and analytic methods, we now recognize that these diseases arise as a result of a dysregulated immune response to intestinal microflora in a genetically susceptible individual. Over 150 genes have been identified that contribute to the pathogenesis of these disease, influencing innate and adaptive immune responses and integrity of the intestinal barrier. The intestinal microflora demonstrate a dysbiotic pattern with reduced diversity and altered abundance of pro‐ and anti‐inflammatory bacterial species. Therapeutic paradigms have evolved with our understanding of the benefit of effective treatment early in the course of disease and the role of combination therapy to reduce immunogenicity and increase the likelihood of sustained response. Whereas therapy for IBD was initially restricted to broad, non‐selective immunosuppressive therapy, emerging treatments increasingly target specific inflammatory pathways such as tumor necrosis factor α, adhesion molecules, and the IL‐23 pathway. Yet this scientific and therapeutic revolution has made the management of these diseases more complex than ever before.
Part I describes the epidemiology and pathogenesis of IBD, including the role of genetics, the environment, and the gut microbiome. We discuss the clinical features and procedures that aid in establishing a diagnosis of Crohn’s disease and ulcerative colitis. We also discuss the various manifestations of IBD that occur outside the intestine and are a source of morbidity to a significant fraction of patients. We discuss the evolution of these diseases towards more complicated behavior and identify relevant risk factors.
Part II discusses each of the classes of therapeutic agents used for the management of IBD, and systematically examines the efficacy of each class in the treatment of patients with ulcerative colitis or Crohn’s disease. We also discuss the safety of each category and review newer therapeutic modalities such as those aimed at the microbiome.
Part III presents practical algorithms for the medical and surgical management of ulcerative colitis and Crohn’s disease, stratifying by severity and extent of involvement. We also review the disease‐specific complications for each IBD subtype and the management of these complications.
Part IV reviews some special clinical considerations in the management of these diseases, including the role of nutrition and dietary therapies, and two commonly encountered clinical scenarios – the management of IBD during pregnancy and in children – ending with a discussion of transition of care.
Throughout this book, learning is facilitated by practical take‐home points in each chapter and patient‐centered questions reviewing the material covered in each chapter. Overall, we hope that this guide will enable clinicians to provide the best help to their patients with IBD through the many challenges that they may face.
Section IPathogenesis and Clinical Features
1Epidemiology and Pathogenesis
Clinical Take Home Messages
Inflammatory bowel diseases (IBDs) have a peak incidence in the second through fourth decades of life but may have their onset at any age.
Most studies have suggested comparable rates of incidence across both genders but risk of disease varies among ethnic populations, e.g., higher frequency in the Ashkenazi Jewish population.
Family history is the strongest risk factor for development of IBD. At least 163 distinct genetic polymorphisms have been described in association with Crohn’s disease (CD) or ulcerative colitis (UC) but explain less than one‐quarter of the variance in risk for either disease.
Disease risk alleles highlight the importance of various genetic pathways in the pathogenesis of these diseases, including innate immunity, adaptive immune response, intestinal barrier function, and pathogen sensing and response. However, polymorphisms at these loci have not been consistently associated with natural history and phenotype of IBD except for correlation between NOD2 polymorphisms and ileal fibrostenosing CD.
Several environmental factors may influence risk of disease and subsequent natural history. The most robust data support an effect of cigarette smoking (increasing risk of CD and reducing risk of UC), but other factors including diet, stress and depression, antibiotic exposure, environmental hygiene, vitamin D, physical activity, and hormones may play a role.
Epidemiology
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, immunologically mediated diseases. They may occur at any age but most often have an onset during young adulthood and a protracted course characterized by remissions and relapses over the course of their natural history. They affect an estimated 2.2 million individuals in Europe and 1.5 million in the United States. The incidence and prevalence appear to be increasing in areas of the world where historically rates have been far lower than found in Northern Europe and North America, such as Asia. The peak age of onset of CD is between 20 and 30 years whereas UC has a peak incidence a decade later between the ages of 30 and 40 years. However, up to 15% of patients may have their first presentation of inflammatory bowel disease (IBD) after the age of 65 years, and a bimodal pattern of incidence with a second smaller peak in the sixth and seventh decades of life has been described, particularly for UC. In addition, a subset of patients can manifest IBD at a very early age, less than 2 years old, termed very early‐onset IBD (VEOIBD), which is characterized by distinct genetic predisposition and clinical phenotype characterized by treatment refractoriness, severe perianal disease, and response to bone marrow transplant.
The incidence of UC in several countries in the Western Hemisphere is informed by large population‐based cohorts tracking secular trends. However, incidence data are lacking from other parts of the world where the emergence of these diseases has been more recent. In North America, the incidence of UC ranges from 0 to 19.2 per 100 000 persons and a similar distribution exists in Europe. CD has a similar incidence, ranging between 0.3 and 12.7 per 100 000 persons in Europe and between 0 and 20.2 per 100 000 persons in North America. Serial estimates of incidence from population‐based cohorts dating back to the mid‐twentieth century reveal interesting secular trends. In Olmsted County, Minnesota, the incidence of UC rose from 0.6 per 100,000 in 1940–1943 to 8.3 per 100 000 in 1990–1993, with the steepest increase in incidence in the 1970s. CD similarly rose from 1.0 per 100,000 person‐years in 1940–1943 to 6.9 cases per 100 000 person‐years in 1984–1993. A systematic review of all studies examining trends in disease incidence suggested that over 75% of the studies involving CD and 60% of the studies involving UC identified secular increases in disease incidence. Virtually no study has reported a consistent decrease in incidence in any population over time. Both CD (incidence 0–5.0 per 100 000) and UC (incidence 0.1–6.3 per 100 000) remain relatively uncommon in Asia compared with Western populations. However, increasing incidence, potentially paralleling westernization of life style, has been found in several Asian countries over the past few decades, including Japan, China, Taiwan, and Korea (Figure 1.1). Interestingly, the incidence for UC generally occurs first, followed a decade later by an increase in the incidence of CD.
Figure 1.1 Geographic variation in incidence of Crohn’s disease and ulcerative colitis.
Source: Adapted from Cosnes et al. 2011 [26]. Reproduced with permission of Elsevier.
There are well‐recognized ethnic differences in risk for CD and UC, and less consistently a difference by gender. In most studies, CD and UC occur equally frequently among men and women, although in some studies there is a slight predominance of men among patients with UC (60%) and a predominance of women among those with CD. The incidence of both diseases is more common in the Jewish population; the risk of CD is 3–8‐fold that of non‐Jews, with a more modest but still elevated risk of UC [1]. The incidence is lower among Sephardic than Ashkenazi Jews and in Israeli than American and European Jews. An international cohort of eight countries in the Asia–Pacific region identified higher incidences of both diseases in Australia than in Asia, but also geographic and ethnic variations within the different countries in Asia [2]. IBD is also uncommon in certain subpopulations even within a high‐incidence geographic region such as the First Nations population in Canada and the Aboriginal population in Australia. Within North America, the prevalence of CD and UC was initially reported to be lower in African American and Hispanic populations, but recent data suggest a rising incidence within these populations and an incidence comparable to the lower end of that reported for Caucasians [3]. The risk of IBD varies with migration from a low‐ to a high‐incidence area. Studies in the United Kingdom and Sweden have demonstrated that the risk, particularly of UC, in immigrants from low‐incidence countries rapidly approaches the rate in the local population within one or two generations. However, this change in risk is dependent on the country of origin. Individuals of South Asian or West Asian origin experience a greater increase in disease risk whereas the risk in those from East Asia remains lower than in the country of residence [4].
Pathogenesis
The key mechanism underlying the development of IBD appears to be a dysregulated immune response to commensal flora in a genetically susceptible individual (Figure 1.2). Family history is one of the strongest risk factors for the development of disease. Only 10–20% of patients will have an affected first‐degree relative. However, the risk of the offspring developing IBD increases 2–13‐fold if one parent is affected. This absolute risk can be as high as 36% if both parents are affected. The concordance of disease is greater in monozygotic twins (30–35%) than dizygotic twins, also supporting an important role for genetics in these diseases. However, genetic mutations alone are not sufficient for disease except in the rare VEOIBD owing to high‐penetrance mutations involving the interleukin (IL)‐10 receptor.
Figure 1.2 Inflammatory bowel disease develops as a result of a complex interplay between genetics, the microbiome, immunologic dysregulation, and the external environment.
Genetics
An international consortium has identified 163 common risk loci for IBD. Most loci are shared between both diseases; 30 loci are distinctly associated with CD whereas 23 loci demonstrate genome‐wide significant association with UC alone. These loci together explain only 13.6% of the variance in risk of CD and 7.5% of the variance in risk for UC. Although most common loci demonstrate an effect in the same direction, two loci demonstrate divergent effects. NOD2 and PTPN22 polymorphisms are associated with an increased risk of CD but are inversely associated with UC. Several of the loci are also implicated in other autoimmune diseases, including psoriasis and celiac disease, suggesting considerable sharing of pathogenic pathways across various autoimmune or inflammatory diseases. Although the spectrum of immunologic disruption as a consequence of these genetic polymorphisms is wide, several pathways emerge as being important in the development of IBD. These include the innate immunity, autophagy, adaptive immune responses, pathogen sensing, maintenance of the intestinal barrier through the mucous layer and epithelial integrity, and response to oxidative stress. Several genes may influence the same pathway. For example, HNF4A, MUC19, CDH1, and GNA12 all influence intestinal barrier integrity whereas NOD2, ATG16L1, IRGM, and LRRK2 affect autophagy. The pathways may act in isolation, in combination with each other, or in conjunction with environmental insults. For example, the functional consequences of autophagy defects on Paneth cell function are triggered by infection with the Norovirus. The identified genetic polymorphisms also highlight the substantial evolutionary conversation between pathways that are important in the development of autoimmune diseases, but also play an important role in mediating responses to infections. For example, polymorphisms in the vitamin D receptor (VDR) or SLC11A1, both linked to IBD, are also associated with increased risk of Mycobacterium tuberculosis infection, and NOD2 and LRRK2 polymorphisms are associated with leprosy. Some of the IBD risk variants (STAT3, CARD9) are also associated with primary immunodeficiency states and may predispose to recurrent bacterial or fungal infections.
NOD2 was the first genetic variant to be associated with CD [5, 6]. It functions as an intracellular sensor of the peptidoglycan muramyl dipeptide (MDP), a component of bacterial cell walls. Stimulation of NOD2 by MDP results in activation of a cascade of inflammatory pathways involving nuclear factor‐κB (NF‐κB) and mitogen‐activated protein (MAP) kinase signaling resulting in the production of inflammatory cytokines including tumor necrosis factor alpha (TNF‐α) and IL‐1β. Three common polymorphisms – Arg702Trp, Gly908Arg, and Leu1007fsX1008 – and five rare variants in NOD2 have been identified through deep sequencing. NOD2 also activates T'cell responses through MDP‐independent mechanisms. Despite NOD2 variants being associated with the greatest relative risk of CD, their presence alone is not sufficient for disease as up to 30% of individuals of European ancestry may carry such variants. In addition, NOD2 has not been consistently associated with CD in non‐European populations.
Variants in genes whose products contribute to autophagy, a cellular process involved in intracellular microbial clearance and degradation of cytosolic contents, have also been associated with CD, most notably variants of ATG16L1 and IRGM. In addition to their independent effect, autophagy variants may influence susceptibility to environmental triggers through a “two‐hit” hypothesis. This was highlighted in an elegant study in which the defects in Paneth cell structure and function in ATG16L1 knockout mice were exaggerated in the setting of murine Norovirus infection [7].
Adaptive immune responses, through both T‐ and B‐lymphocytes, play an important role in the pathogenesis of IBD. In the setting of active inflammation, naive T cells are activated and differentiate into Th1, Th2, or Th17 cells depending on the influence of different cytokines [8, 9]. Th1 cells, initially thought to be key in the pathogenesis of Crohn’s disease, produce TNF‐α and interferon gamma (IFN‐γ) along with other cytokines that activate macrophages, lead to epithelial cell apoptosis, and induce differentiation of stromal myofibroblasts, which, through the production of matrix metalloproteinases, result in degradation of the extracellular matrix. In contrast, Th2 cells produce IL‐13, which increases intestinal permeability and induces epithelial apoptosis [8, 9].
A relatively recently described class of helper T cells – Th17 cells – produce IL‐17A, IL‐21, and IL‐22, which aid in neutrophil recruitment and inflammation through activation of NF‐κB and MAPK pathways [8, 9]. Several other cell types also appear to play important roles in the pathogenesis of IBD. The innate lymphoid cell (ILC) is a newly described effector cell subtype that makes IFN‐γ (group 1 ILC), IL‐5 and IL‐13 (group 2 ILCs), or IL‐17, IL‐22, and IFN‐γ (group 3 ILCs). Group 3 ILCs in particular appear to play an important role in inducing colitis through an IL‐23R/IL‐22‐dependent mechanism. In an animal model, RAG–/– mice developed colitis after injection of CD40 ligand (CD40L), but only in the presence of innate lymphoid cells [10].
Trafficking of leukocytes to the small intestine and colon, mediated through chemoattractants, chemokine receptors, and adhesion molecules, plays an important role in homing of lymphocytes into gut‐associated lymphoid tissues at the site of inflammation [11]. For example, the mucosal vascular addressin cell adhesion molecule 1 (MADCAM1), expressed on the high endothelial venules of Peyer’s patches and on the venules of small intestine and colon, is a receptor for the α4β7 integrin and facilitates migration of leukocytes to Peyer’s patches and sites of intestinal inflammation [11].
The rapid pace of discovery in the field of genetics and immunopathogenesis of these diseases has contributed to the development of existing and emerging therapeutics and highlighted novel effective modalities of action. Monoclonal antibodies to TNF‐α, reviewed in detail in subsequent chapters, are among the most effective existing treatments for both CD and UC. Recognition of the importance of the IL‐17/IL‐23 pathway in IBD led to the development of an antibody targeting the p40 subunit of IL‐12/IL‐23, ustekinumab, that is already in use for the treatment of psoriasis and shows promise in the management of CD. Leukocyte migration has been targeted by several drug categories, including monoclonal antibodies such as natalizumab and vedolizumab, and also small‐molecule inhibitors. The direct implication of genotype in guiding a personalized approach to diagnosis or therapy is less well established. NOD2 mutations are associated with ileal location or fibrostenosing CD. None of the other genetic mutations have been consistently predictive of natural history or response to therapy, although panels comprising multiple genes show a modest ability to predict therapy response.
Microbiome
Several lines of evidence support an important role for the intestinal microbiome in the pathogenesis of IBD. Mice genetically predisposed to develop colitis, such as IL10–/– or TCRα–/–, either do not develop colitis in germ‐free conditions, or develop only attenuated inflammation (SAMP1/yit or IL2–/– mice). Defects in pattern recognition receptors such as Toll‐like receptors result in attenuation of the colitis. Several polymorphisms important in the development of IBD, for example NOD2 and ATG16L1, are key for the recognition of patterns from luminal microbial antigens and activation of innate immune responses in response to such stimulation. Polymorphisms at these loci result in aberrant Paneth cell function and impaired production of antimicrobial peptides, further highlighting the importance of luminal microbial antigenic stimulation. Clinically, in patients with CD, exposure to the fecal stream is essential for the development of postoperative recurrence after intestinal resection [12, 13].
The normal adult human microbiome contains 1013–1014 bacterial cells and an estimated 1000 different bacterial species. The largest microbial community in the human intestine is Bacteroidetes with a smaller proportion of Firmicutes. Other important groups occurring at a lower frequency are Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia. There is substantial inter‐individual variation in the intestinal microbiome, which attains stability after the first 2–4 years of life. The intestinal microbiota is also susceptible to the effect of external environmental influences, most prominently diet and antibiotic exposure.
Three dominant patterns of gut microbial changes are apparent in patients with IBD. First, there is an overall reduction in diversity and abundance of gut microbiota in patients with IBD compared with controls. Mucosal biopsies in IBD demonstrate a reduced abundance of Firmicutes and Bacteroidetes and an increase in Proteobacteria and Actinobacteria [14, 15]. Second, specific subphenotypes of IBD may demonstrate an increase in some pathogenic microbes. Specifically, enteroadherent Escherichia coli is found at a greater frequency in ileal lesions of patients with CD than with UC or in healthy controls [16]. Third, patients with IBD may demonstrate a reduced frequency of bacteria, which may be important in conferring protection from intestinal inflammation. For example, individuals with IBD have reduced levels of short‐chain fatty acids in stool, pointing to the potential role of Ruminococcaceae, which are important butyrate producers. They also have reduced abundance of Faecalibacterium prausnitzii, a bacterium belonging to the Clostridiales family. Furthermore, the prevalence of F. prausnitzii correlates inversely with likelihood of endoscopic recurrence of CD following intestinal resection and supernatants from F. prausnitzii cultures ameliorate colitis in animal models [17, 18]. In addition to the above variations in composition of the gut microbiome, there are also differences in functional pathways between IBD and healthy individuals, including those mediating response to oxidative stress, and a decrease in carbohydrate and amino acid biosynthesis [19]. However, bacteria may not be the sole components of the gut microbiome influencing susceptibility to IBD. Viral infections, particularly in the context of specific genetic polymorphisms, may act as triggers for intestinal inflammation and disruption of immune function [7]. Fungal diversity may be increased in patients with IBD.
Environmental Triggers
Several environmental factors appear to influence the risk of and natural history of IBD. Harries et al. [20] first noted that patients with UC were less frequently smokers than healthy individuals. Several studies since have replicated this association and demonstrated an increased risk of CD among current and former smokers. In contrast to the inverse association between current smoking and UC, smoking cessation is associated with a twofold increase in risk of UC that is apparent within 2–5 years of cessation and may persist for up to 20 years. Passive smoking has a similar direction of effect. The effect of smoking is not uniform in all populations and may be dependent on ethnicity and gender. Women are more susceptible to the adverse effects of smoking on IBD whereas men have a greater magnitude of the protective effect of cigarette smoke on UC. Smoking exerts an influence on natural history of disease similar to its effect on incident disease. Current smokers have more aggressive CD with a greater need for immunosuppression, a higher likelihood of surgery, and increased risk of recurrence after resection. In contrast, in UC, smoking is associated with a milder course and reduced likelihood of surgery. It is unclear which substance(s) within tobacco smoke are responsible for these effects. Trials with nicotine‐based agents do not ameliorate disease in patients with UC. A similar interesting divergent direction of effect is seen for appendectomy. When performed before the age of 20 years and for inflammatory appendicitis, it is associated with a reduced risk of UC [21]. In contrast, it does not confer similar protection against CD and may be associated with an increased risk.
Given the central role of the microbiome in disease pathogenesis and the strong influence of long‐ and short‐term diet on gut composition, it is plausible that diet plays a role in the predisposition to developing IBD or influences subsequent natural history. However, high‐quality prospective data informing such associations are lacking. The most consistent dietary association described is an inverse relationship between fruits, vegetables, or fiber intake and risk of CD. Several plausible mechanisms support this association. Soluble fiber may prevent bacterial transmigration through the epithelium and modify the composition of gut microbiota. Specific dietary substances may be ligands for the aryl hydrocarbon receptor, which plays a role in ameliorating gut inflammation. Dietary fat may increase the risk of UC although the data are less consistent and many studies have shown no effect. However, in animal models, a high milk fat diet resulted in expansion of pathobionts in the gut and more severe colitis. n‐3 polyunsaturated fatty acids such as are found in fish oil have been inversely associated with risk of UC, although therapeutic interventions modifying their intake have yielded mostly unsuccessful results in both CD and UC. Studies have also demonstrated substantial heterogeneity in susceptibility to symptomatic exacerbations in response to the intake of specific foods. Therapeutically, elemental diet is effective in inducing remission in pediatric CD but is poorly tolerated over the long term. Several other elimination diets have been proposed but there is a lack evidence in support of efficacy.
Other environmental influences associated with risk of IBD include antibiotic exposure, low vitamin D, sleep, stress and depression, physical activity, hormone use, non‐steroidal anti‐inflammatory drugs (NSAIDs) and aspirin, breastfeeding, environmental hygiene, and exposure to animals in childhood. Although offering intriguing insights into disease pathogenesis, few of these have been translated into interventions to benefit individuals with established disease. Normalization of vitamin D levels in patients with deficiency is associated with a reduction in risk of subsequent surgeries, and vitamin D supplementation may reduce the likelihood of relapses. Interventions targeting stress and depression may improve psychological quality of life but have a variable impact on actual clinical disease activity. Enteric infections, in particular Clostridium difficile infection, are frequent triggers of relapses in those with established IBD and should be sought for in the setting of unexplained clinical activity (Table 1.1). Although ascertaining exposure to some of these potential triggers at the time of disease exacerbation is reasonable, with the exception of smoking cessation in those with established CD, systematic efforts to modify these risk factors with the aim of influencing overall disease activity cannot be recommended due to lack of high‐quality interventional studies.
Table 1.1 Effect of environmental risk factors on risk of development of Crohn’s disease or ulcerative colitis.
Environmental factor
Crohn’s disease
Ulcerative colitis
Smoking
Current smoking
Increased risk
Decreased risk
Former smoking
Increased risk
Increased risk
Appendectomy
Equivocal
Decreased risk
Diet
Dietary fiber, Fruits, vegetables
Reduces risk
No effect
Dietary fat
Equivocal
High n‐3 polyunsaturated fats may reduce risk whereas n‐6 fats may be associated with increased riskSaturated fat diet (particularly milk fat) may be associated with increased risk
Protein
Equivocal
Equivocal. May increase risk
Zinc
Decreased risk
No effect
Stress, depression
Increased risk
Increased risk
NSAIDs, aspirin
Increased risk
Increased risk
Low vitamin D levels
Increased risk
No effect
Antibiotic use
Increased risk
Increased risk
History of being breastfed
Decreased risk
Decreased risk
Case Studies and Multiple Choice Questions
John is a 26‐year‐old male who presented to his gastroenterologist with complaints of diarrhea and rectal bleeding of 4 months’ duration. He has no extraintestinal symptoms. He has no family history of IBD. A colonoscopy is performed and reveals erythema, granularity, friability, and erosions consistent with left‐sided ulcerative colitis. Which of the following factors if present in John’s history is associated with an increased risk of ulcerative colitis?
Increased intake of dietary fiber.
A history of appendectomy at age 9 years for appendicitis.
Current smoking of one pack per day.
Smoking cessation 2 years prior to diagnosis.
The proportion of patients with IBD who will have at least one affected first‐degree relative with Crohn’s disease or ulcerative colitis is
0–5%.
10–20%.
50–60%.
80–90%.
Which of the following changes in the gut microbiome have
not
been described in patients with IBD?
Increased frequency of enteroinvasive
Escherichia coli
.
Reduced diversity of gut microbiota.
Reduced abundance of bacteria belonging to the phylum Firmicutes.
Greater abundance of
Faecalibacterium prausnitzii
.
The known 163 common single‐nucleotide polymorphisms that modify risk of Crohn’s disease or ulcerative colitis explain what proportion of the variance in risk for each disease?
8% of the variance in UC and 14% of the variance in CD.
22% of the variance in UC and 48% of the variance in CD.
60% of the variance in UC and 30% of the variance in CD.
5% of the variance in UC and 20% of the variance in CD.
References
1 Fireman, Z., Grossman, A., Lilos, P.,
et al
. (1989) Epidemiology of Crohn’s disease in the Jewish population of central Israel, 1970–1980.
American Journal of Gastroenterology
,
84
(3), 255–258.
2 Ng, S.C., Tang, W., Ching, J.Y.,
et al
. (2013) Incidence and phenotype of inflammatory bowel disease based on results from the Asia–Pacific Crohn’s and Colitis Epidemiology Study.
Gastroenterology
,
145
(1), 158–165.e2.
3 Hou, J.K., El‐Serag, H., and Thirumurthi, S. (2009) Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review.
American Journal of Gastroenterology
,
104
(8), 2100–2109.
4 Li, X., Sundquist, J., Hemminki, K., and Sundquist, K. (2011) Risk of inflammatory bowel disease in first‐ and second‐generation immigrants in Sweden: a nationwide follow‐up study.
Inflammatory Bowel Diseases
,
17
(8), 1784–1791.
5 Hugot, J.P., Chamaillard, M., Zouali, H.,
et al
. (2001) Association of NOD2 leucine‐rich repeat variants with susceptibility to Crohn’s disease.
Nature
,
411
(6837), 599–603.
6 Ogura, Y., Bonen, D.K., Inohara, N.,
et al
. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease.
Nature
,
411
(6837), 603–606.
7 Cadwell, K., Patel, K.K., Maloney, N.S.,
et al
. (2010) Virus‐plus‐susceptibility gene interaction determines Crohn’s disease gene Atg16L1 phenotypes in intestine.
Cell
,
141
(7), 1135–1145.
8 Wallace, K.L., Zheng, L.B., Kanazawa, Y., and Shih, D.Q. (2014) Immunopathology of inflammatory bowel disease.
World Journal of Gastroenterology
,
20
(1), 6–21.
9 Geremia, A., Biancheri, P., Allan, P.,
et al
. (2014) Innate and adaptive immunity in inflammatory bowel disease.
Autoimmunity Reviews
,
13
(1), 3–10.
10 Buonocore, S., Ahern, P.P., Uhlig, H.H.,
et al
. (2010) Innate lymphoid cells drive interleukin‐23‐dependent innate intestinal pathology.
Nature
,
464
(7293), 1371–1375.
11 Habtezion, A., Nguyen, L.P., Hadeiba, H., and Butcher, E.C. (2016) Leukocyte trafficking to the small intestine and colon.
Gastroenterology
,
150
(2), 340–354.
12 Rutgeerts, P., Goboes, K., Peeters, M.,
et al
. (1991) Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum.
Lancet
,
338
(8770), 771–774.
13 D’Haens, G.R., Geboes, K., Peeters, M.,
et al
. (1998) Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum.
Gastroenterology
,
114
(2), 262–267.
14 Frank, D.N., St. Amand, A.L., Feldman, R.A.,
et al
. (2007) Molecular‐phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases.
Proceedings of the National Academy of Sciences of the United States of America
,
104
(34), 13780–13785.
15 Ott, S.J., Musfeldt, M., Wenderoth, D.F.,
et al
. (2004) Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease.
Gut
,
53
(5), 685–693.
16 Sepehri, S., Khafipour, E., Bernstein, C.N.,
et al
. (2011) Characterization of
Escherichia coli
isolated from gut biopsies of newly diagnosed patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
,
17
(7), 1451–1463.
17 Sokol, H., Seksik, P., Furet, J.P.,
et al
. (2009) Low counts of
Faecalibacterium prausnitzii
in colitis microbiota.
Inflammatory Bowel Diseases
,
15
(8), 1183–1189.
18 Sokol, H., Pigneur, B., Watterlot, L.,
et al
. (2008)
Faecalibacterium prausnitzii
is an anti‐inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.
Proceedings of the National Academy of Sciences of the United States of America
,
105
(43), 16731–16736.
19 Morgan, X.C., Tickle, T.L., Sokol, H.,
et al
